CGMP Violations Seen in Shenzhen Records Review
FDA says its review of records requested on 1/20 from Shenzhen Benliju Biotech Co., Ltd., in Shenzhen, China, identified current good manufacturing practice (CGMP) violations in the firm’s manufacturing of over-the-counter drug products. A just-released 11/6 Warning Letter says specific violations were:
- failure to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, before release, and failure to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms;
- failure to establish written procedures for production and process control designed to assure that manufactured drug products have the identity, strength, quality, and purity they purport or are represented to possess; and
- failure of the firm’s quality unit to exercise its responsibility to ensure that manufactured drug products comply with CGMP and meet established specifications for identity, strength, quality, and purity.
FDA acknowledges that the company agreed to an agency suggestion that it recall all lots of a redacted product within expiry that are labeled as “sterile” since the company has not demonstrated that the products are sterile.
The agency recommends that Shenzhen engage a qualified consultant to perform a comprehensive six-system audit of its entire operation for CGMP compliance, assist it in meeting CGMP requirements, and evaluate the completion and efficacy of the company’s corrective and preventive actions before the company pursues resolution of its FDA compliance status.
Shenzhen was told to promptly address the violations and ensure that appropriate resources are allocated to fully address the violations and prevent their recurrence.